Stockscreener 앱 받기
0.6091
4.05%
0.0237
시간 외 거래:
.58
-0.0291
-4.78%
전일 마감가:
$0.5854
열려 있는:
$0.592501
하루 거래량:
163.09K
Relative Volume:
0.15
시가총액:
$20.27M
수익:
-
순이익/손실:
$-55.73M
주가수익비율:
-0.1887
EPS:
-3.2274
순현금흐름:
$-68.87M
1주 성능:
-1.41%
1개월 성능:
-15.43%
6개월 성능:
-44.12%
1년 성능:
-73.86%
1일 변동 폭
$0.5787
$0.6199
1주일 범위
$0.5443
$0.6698
52주 변동 폭
$0.3151
$2.69
Jasper Therapeutics Inc Stock (JSPR) Company Profile
명칭
Jasper Therapeutics Inc
전화
(650) 549-1400
주소
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
0.6091 | 19.48M | 0 | -55.73M | -68.87M | -3.2274 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-23 | 재개 | UBS | Neutral |
| 2026-01-13 | 개시 | Rodman & Renshaw | Buy |
| 2025-07-08 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | 개시 | UBS | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-09-09 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-08 | 개시 | BTIG Research | Buy |
| 2024-06-27 | 개시 | Stifel | Buy |
| 2024-05-06 | 개시 | H.C. Wainwright | Buy |
| 2024-04-03 | 개시 | Evercore ISI | Outperform |
| 2024-03-28 | 개시 | RBC Capital Mkts | Outperform |
| 2024-03-18 | 개시 | TD Cowen | Outperform |
| 2023-08-11 | 개시 | CapitalOne | Overweight |
| 2022-02-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 개시 | Credit Suisse | Outperform |
| 2021-10-21 | 개시 | William Blair | Outperform |
| 2021-10-20 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-13 | 개시 | Oppenheimer | Outperform |
모두보기
Jasper Therapeutics Inc 주식(JSPR)의 최신 뉴스
Ten Jasper Therapeutics (JSPR) warrants are exercisable for one share as Nasdaq moves to remove their listing. - Stock Titan
Jasper Therapeutics stock gains 1.39 percent on Nasdaq - AD HOC NEWS
Jasper Therapeutics stock holds at USD 5.42 as pipeline data guide trading - AD HOC NEWS
Jasper Therapeutics stock holds recent gains as investors watch latest trial and funding data - AD HOC NEWS
Jasper Therapeutics, Inc.(NasdaqCM: JSPR) added to NASDAQ Composite Index - marketscreener.com
JSPR: Merger yields robust pipeline and funding, with major clinical and regulatory milestones ahead - TradingView
Jasper Therapeutics at H.C. Wainwright: cash and catalysts By Investing.com - Investing.com Canada
JSPR: Merger creates a robust immunology pipeline with major clinical and regulatory milestones ahead - TradingView
Jasper Therapeutics appoints two executives to key roles By Investing.com - Investing.com Australia
Jasper Therapeutics appoints two executives to key roles - Investing.com
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments - Yahoo Finance
A biotech company's New York talk will be webcast live - Stock Titan
Jasper Therapeutics (NASDAQ: JSPR) Schedules September 30 Vote on Increasing Authorized Common Stock - kalkinemedia.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Jasper Therapeutics Inc (JSPRW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Jasper Therapeutics Inc (JSPRW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Jasper Therapeutics (NASDAQ: JSPR) on clock after Nasdaq equity warning - Stock Titan
Jasper (JSPR) Latest: Gains 3.59% to Reach $0.72 in Latest Trading; Price Levels: Price Remains Between $0.68 Support and $0.76 Resistance under the Current SnapshotLong Setup Ideas - vinanet.vn
Wenru Song Net Worth (2026) - GuruFocus
Kira Pharmaceuticals - The Pharma Letter
Jasper Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Velan group shifts to passive stake in Jasper (NASDAQ: JSPR) - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Jasper Therapeutics beats Q2 expectations but shares fall after results - Yahoo Finance
Jasper Therapeutics beats earnings expectations but stock falls 4% By Investing.com - Investing.com South Africa
Jasper Therapeutics beats earnings expectations but stock falls 4% - Investing.com
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com
JSPR Q1 2026 Earnings: 91.94% EPS Beat Signals Cost Discipline, But Stock Slips 8.46%Earnings Season Preview - vinanet.vn
Jasper Therapeutics Q2 EPS of $(0.10) beats estimates - scanx.trade
Jasper Therapeutics (JSPR) narrows Q2 2026 loss, closes Kira deal and $132M PIPE - Stock Titan
Jasper Therapeutics Reports $2.8 Million Second-Quarter Net Loss - Quiver Quantitative
Jasper Therapeutics, Inc. (JSPR) stock: Climbs on Kira Merger and $132M Raise as Pipeline Consolidates - Blockonomi
Jasper Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln - TradingView
Jasper Therapeutics, Inc. 2Q 2026: Net loss $(2.8M), EPS $(0.10) — 10-Q Summary - TradingView
Jasper Therapeutics Reports Q2 2026 Results and Completion of Kira Pharmaceuticals Acquisition - Quiver Quantitative
JSPR Financials: Income Statement, Balance Sheet & Cash Flow | Jasper Therapeutics Inc - Stock Titan
Jasper Therapeutics (JSPR) slashes losses, acquires Kira and raises $132M - Stock Titan
Piper Sandler Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $2 - Moomoo
Piper Sandler initiates Jasper Therapeutics stock at overweight By Investing.com - Investing.com Canada
Piper Sandler Initiates Jasper Therapeutics With Overweight Rating, $2 Price Target - Yahoo Finance
$Jasper Therapeutics (JSPR.US)$ Goodbye - Moomoo
JSPR DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC - The National Law Review
Jasper Therapeutics Inc (JSPR) Stock News Today - TradingKey
Jasper Therapeutics Inc (JSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jasper Therapeutics, Inc. expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Jasper Therapeutics (NASDAQ:JSPR): Why Is the Stock Back in Focus as the Latest Update Arrives? - Kalkine Media
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirt - The National Law Review
JSPR Completes Briquilimab Trial In Chronic Hives, Setting Up Next Risk–Reward Catalyst - TipRanks
Jasper Therapeutics Halts Briquilimab Extension Study in Chronic Urticaria: What Investors Should Know - TipRanks
JSPR Q2'26 Earnings: EPS estimate is (0.25) USD - TradingView
Jasper Therapeutics Inc (JSPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):